Huons Decides to Absorb Subsidiary Huons Lab - Merger Ratio 1:0.4257, 3.83M New Shares (24.20% Dilution)

Huons decided to absorb its subsidiary Huons Lab with a merger ratio of 1:0.4256893, issuing 3,825,327 new shares (24.20% dilution)
Huons Lab is an unlisted biopharmaceutical R&D company with negative equity of KRW -1.8 billion and net loss of KRW 10.2 billion as of end-2025
The merger aims to strengthen new drug pipelines and build a full value chain for biopharmaceuticals to enhance global competitiveness
The appraised value per share is KRW 34,062 for Huons and KRW 14,500 for Huons Lab, deemed fair by external evaluator Ichon Accounting
The expected buyback price for appraisal rights is KRW 32,886; Huons may cancel the merger if total buyback exceeds KRW 30 billion
Stock price recently rose from KRW 26,150 in March 2026 to KRW 34,800 in May 2026

Filing: Report on Major Matters (Decision on Company Merger) (Major Management Matters of Subsidiary)
Company: Huons Global (084110)
Submission: Huons Global Co., Ltd.
Receipt: 05-18-2026
Under KRX KOSDAQ Market Division